Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health Companies (NYSE/TSX: BHC) will present seven scientific posters and data from its ARMOR surveillance study at the American Academy of Optometry and American Academy of Ophthalmology meetings held in November 2021. Key presentations include analyses on the newly FDA-approved XIPERE™ for macular edema and the Bausch + Lomb INFUSE® Multifocal contact lenses. The company's commitment to educating eye care professionals through promotional events highlights its dedication to addressing patient needs.
Bausch Health has launched the Biotrue® Eye Care Recycling program, the first of its kind in the United States, allowing consumers to recycle eye drop single dose units, lens cases, and Biotrue® multi-dose bottles. This initiative, in collaboration with TerraCycle, aims to reduce environmental waste from these products. Participants can sign up for the program, collect eligible items, and mail them to TerraCycle for proper recycling. The program supports Bausch's ongoing commitment to sustainability in eye care packaging.
Bausch Health and its subsidiary Salix Pharmaceuticals released the Liver Health Annual Trends Report, highlighting critical gaps in chronic liver disease (CLD) care in the U.S. The report surveyed 100 healthcare providers, revealing that 38% are unaware of CLD management guidelines. An alarming 51% do not follow current American Association for the Study of Liver Diseases (AASLD) guidelines. CLD affects approximately 4.5 million Americans, with increasing cases of nonalcoholic fatty liver disease noted. The report emphasizes the urgent need for improved education and adherence to treatment standards.
Bausch Health Companies Inc. (BHC) announced the presentation of seven research findings related to its products XIFAXAN®, TRULANCE®, and RELISTOR® at the American College of Gastroenterology 2021 Annual Scientific Meeting in Las Vegas, from October 22-27, 2021. The new clinical data aims to improve patient care for gastrointestinal disorders. Salix Pharmaceuticals, a subsidiary, leads this initiative, reflecting its commitment to advancing gastrointestinal health.
XIPERE™, approved by the FDA, is the first medication for suprachoroidal injection in the U.S., targeting macular edema associated with uveitis. Developed by Bausch Health (BHC) and Clearside Biomedical (CLSD), it facilitates targeted delivery to the retina, potentially mitigating vision loss. Clinical trials indicate that 47% of patients showed significant visual acuity improvement compared to 16% in the control group. The product will be available in Q1 2022, offering a new therapeutic option in the eye health market.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has appointed Tom Vadaketh as Chief Financial Officer (CFO) of Bausch Pharma, effective January 3, 2022. Sam Eldessouky will transition to CFO of Bausch + Lomb following its IPO completion. Vadaketh brings over 30 years of financial experience from various roles, including CFO positions at reputable firms. This leadership change aims to strengthen Bausch Pharma's financial management as they prepare for the IPO of their eye health business. The company emphasizes its commitment to advancing global health through innovative products.
Bausch Health Companies (NYSE/TSX: BHC) announced the presentation of eight posters at the Fall Clinical Dermatology Conference from Oct. 21-24, 2021. These posters will showcase analyses of the efficacy and safety of ARAZLO® (tazarotene) Lotion, DUOBRII® (halobetasol propionate and tazarotene) Lotion, and SILIQ® (brodalumab) injection. The presentations include key findings on long-term outcomes, quality of life improvements, and treatment recommendations for onychomycosis. Two educational events focusing on ARAZLO and DUOBRII will also be held during the conference.
Bausch + Lomb announced positive outcomes from the one-year evaluation of its LuxSmart™ lens, designed for continuous vision from distance to intermediate. Since its 2020 European launch, 5,000 cataract patients have been treated with the lens, adopted by 200 surgeons across 18 countries. Evaluation results indicate excellent vision performance with minimal dysphotopsia. The lens is preloaded and suitable for patients with co-morbidities, with up to 30% of patients gaining near vision.
There is a growing global market for presbyopia solutions, with an expected 1.8 billion people affected by 2050.
Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its third-quarter 2021 financial results on November 2, 2021, at 8:00 a.m. ET. The event will include a conference call for discussion on the results and a business update, accessible via the company's Investor Relations site. The company specializes in pharmaceutical, medical devices, and over-the-counter products focusing on eye health, gastroenterology, and dermatology.
Bausch Health and Novaliq announced statistically significant topline results from the MOJAVE Phase 3 trial of NOV03, a novel eye drop treatment for dry eye disease associated with Meibomian gland dysfunction. The trial met primary endpoints, showing significant improvements in total corneal staining and dryness scores at day 57, p 0.001. These findings reaffirm the safety and efficacy observed in earlier trials. A New Drug Application to the FDA is anticipated in 2022, potentially marking a significant advancement in treating millions suffering from dry eye disease.